Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial ...

AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Global life sciences leader AbbVie says it has entered into a voluntary agreement with the Trump administration to further ...

Alvotech ( ($ALVO) ) has provided an update. On December 31, 2025, Alvotech announced it had secured a new USD 100 million senior term loan ...